Boehringer Ingelheim to cash out Hikma stake; Breast cancer biotech sets terms for IPO
→ Boehringer Ingelheim is offloading a major chunk of its holding in Hikma, proposing to sell 28 million out of 40 million shares of the London-listed drugmaker. The stake is valued at nearly £1 billion, and Hikma has committed to buying no more than £295 million of it — which would amount to 4.99% of its stock’s value at the time the deal was unveiled. The German pharma giant had obtained these shares when it sold Roxane Laboratories to Hikma in 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.